“Ca cervix” covers a large syllabus. Here is the study map:
-
Epidemiology and risk factors
HPV, sexual/reproductive risk factors, HIV/immunosuppression, prevention.
-
Pathogenesis and pathology
Transformation zone, HPV oncogenesis, CIN/HSIL, histologic types and molecular classification.
-
Screening and primary prevention
HPV vaccination, HPV DNA testing, cytology, co-testing, visual inspection methods, current screening updates.
-
Clinical presentation and diagnosis
Symptoms, examination, colposcopy, biopsy, conization, staging work-up.
-
FIGO staging and investigations
Current FIGO 2018 staging, imaging, nodal assessment, fertility implications.
-
Management by stage
Preinvasive disease, early-stage cancer, locally advanced disease, metastatic/recurrent cancer, pregnancy and fertility-sparing care.
-
Radiotherapy and systemic therapy
Concurrent chemoradiation, brachytherapy, chemotherapy, immunotherapy, targeted and antibody-drug conjugate therapies.
-
Follow-up, recurrence, prognosis, and palliative care
-
Recent updates
WHO elimination targets; HPV self-sampling; primary HPV screening; pembrolizumab-based first-line therapy; cemiplimab; tisotumab vedotin; and evolving management after chemoradiation.
At a high level, cervical cancer is predominantly an HPV-driven squamous-cell carcinoma arising in the transformation zone. Prevention through HPV vaccination and screening is central. Disease confined to the cervix can often be cured with surgery or radiotherapy, whereas locally advanced disease is usually treated with pelvic external-beam radiotherapy plus weekly cisplatin and image-guided brachytherapy. Recurrent or metastatic disease increasingly uses biomarker-guided immunotherapy and antibody-drug conjugates.